Portfolio Rapha Capital Management

Rapha Capital Management Participates in Series C Financing for Poseida Therapeutics, Inc. Led by Novartis Pharmaceuticals

By Kevin SlawinApril 22, 2019February 4th, 2021No Comments

Poseida Therapeutics and Rapha Capital Management
Rapha Capital Management Participates in Series C Financing for Poseida Therapeutics, Inc. Led by Novartis Pharmaceuticals
April 22, 2019

Previous PostAsclepiX Therapeutics Selected to Present at Ophthalmology Innovation Summit (OIS) at the American Society for Retinal Surgeons (ASRS) Annual Conference
Next PostPoseida to Advance CAR-T For Myeloma with Novartis-Led $142M Round

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions